Member Info for Beamer21

The group said the sharing agreement provides the opportunity for the company to benefit from positive future share price performance.

Immupharma said the proceeds of the subscription will be used primarily to fund the execution of its corporate strategy, as announced on 7 May 2019, including progressing Lupuzor through both corporate partnerships and regulatory pathways and proactively pursuing the 'spin-off' of the subsidiary companies, Ureka and ELRO, in order to unlock their future potential and enhance value to shareholders.

Commenting on the share subscription, ImmuPharma's Chairman, Tim McCarthy, said: ”Lanstead has been very supportive of the Company since their first investment in 2016 and this latest subscription demonstrates their continued support and the alignment of both the Company and Lanstead's belief of the potential of substantial value enhancement for shareholders in the future execution of the Company's recently stated corporate strategy."

Agree, this is a solid share to have in the portfolio particularly if holding for the longer term

Already hold a fair amount and been waiting for a lull to top up - missed the temporary drop the other day but to be honest I don’t think it really matters as this is a steady performer in a very dynamic market

Watched the MS video the other day which instilled further confidence

Glad I saw the RNS when I did - corruption with forward selling provided an opportunity

Now rising

*Stops

Tops and panic selling driving it down - do your research and sit tight

The 12.5m has already been sold - watch your stops

Majorboy - I think some people think there is now 12.5m to be sold down however the 12.5m was forward sold on 21/10 so no more selling

In my opinion BGF forward sold the 12.5m on 21/10 at 2.5p so we should see no more selling

A nice £268,750 pay day after exercising at £43,750

appearing which have caused the drop although steady buying has mitigated a bigger drop

The ticker change is largely irrelevant, the deal has been done but now need to undertake a full rebranding exercise

No change of ticker for a while though

The 410k trade is maybe some kind of a transfer possibly between institutions..... who knows, however the price action appears to be upwards which is positive

What do you make of the delayed trades showing before one today?

of kilter with the 2018 acquisition of MeetingZone for close to £62m

I’ve bought a few

have taken 3.39% - prolific investors, currently hold 4.6% of Evgen amongst several others

at 22.5p

Yes, just due to the spread.

On the right track, focussed on growth but seeing early traction

Solid contract win which will contribute nicely

The reduction in margins has been widely reported for some time so is not a surprise

The Board anticipates incremental improvement with EBITDA loss in H2 2019 expected to be significantly lower and continued progression in FY 2020 as the historic contract book continues to expire.